182 related articles for article (PubMed ID: 23687793)
1. Targeted therapy in advanced urothelial carcinoma.
Verdoorn BP; Kessler ER; Flaig TW
Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
[TBL] [Abstract][Full Text] [Related]
2. Advanced urothelial carcinoma: moving the field forward.
Milowsky MI
Oncology (Williston Park); 2013 Mar; 27(3):233-4, C3. PubMed ID: 23687795
[No Abstract] [Full Text] [Related]
3. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
4. Targeted agents in second-line bladder cancer therapy.
Gerullis H; Otto T; Ecke TH
Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
[TBL] [Abstract][Full Text] [Related]
5. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Bellmunt J; Hussain M; Dinney CP
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
[TBL] [Abstract][Full Text] [Related]
7. Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
Dovedi SJ; Davies BR
Cancer Metastasis Rev; 2009 Dec; 28(3-4):355-67. PubMed ID: 19997963
[TBL] [Abstract][Full Text] [Related]
8. "Missing the target" in urothelial cancer.
Dreicer R
Oncology (Williston Park); 2013 Mar; 27(3):227, 233. PubMed ID: 23687794
[No Abstract] [Full Text] [Related]
9. Emerging therapies for urothelial cancer.
Serrano C; Morales R; Suárez C; Núñez I; Valverde C; Rodón J; Humbert J; Padrós O; Carles J
Cancer Treat Rev; 2012 Jun; 38(4):311-7. PubMed ID: 22113129
[TBL] [Abstract][Full Text] [Related]
10. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
11. Targeting Signaling Transduction Pathways in Bladder Cancer.
Abbosh PH; McConkey DJ; Plimack ER
Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
[TBL] [Abstract][Full Text] [Related]
12. Urothelial cancers: using biology to improve outcomes.
Pezaro C; Liew MS; Davis ID
Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
Black PC; Brown GA; Inamoto T; Shrader M; Arora A; Siefker-Radtke AO; Adam L; Theodorescu D; Wu X; Munsell MF; Bar-Eli M; McConkey DJ; Dinney CP
Clin Cancer Res; 2008 Mar; 14(5):1478-86. PubMed ID: 18316572
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
15. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder.
Sadeghi S; Garcia JA
Semin Oncol; 2012 Oct; 39(5):608-14. PubMed ID: 23040257
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel for the treatment of bladder cancer.
Albany C; Sonpavde G
Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Hindy JR; Souaid T; Kourie HR; Kattan J
Future Oncol; 2019 May; 15(13):1505-1524. PubMed ID: 30977669
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
Aragon-Ching JB; Trump DL
Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
[TBL] [Abstract][Full Text] [Related]
20. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
